Multidrug Resistance Tuberculosis—Current Problems

Katarzyna Kruczak; Ewa Niżankowska-Mogilnicka

doi:10.5603/ARM.27809

You are currently viewing a new version of our website. To view the old version click .

Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Review

23 April 2009

Multidrug Resistance Tuberculosis—Current Problems

and

Klinika Pulmonologii, II Katedra Chorób Wewnętrznych, Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, ul. Skawińska 8, 31-066 Kraków, Poland

Author to whom correspondence should be addressed.

Adv. Respir. Med.2009, 77(3), 276-283;https://doi.org/10.5603/ARM.27809

Version Notes

Order Reprints

Abstract

The rising occurrence of multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and rifampicin, is a serious worldwide problem. The treatment of MDR-TB with alternative chemotherapy is difficult due to side-effects and treatment duration. It is also very expensive and sometimes unsuccessful. DOTS and DOTS-Plus strategy are necessary to achieve a good tuberculosis control.

Keywords:

multidrug resistant tuberculosis; extensively drug resistant tuberculosis; DOTS-Plus

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

D-dimer in Diagnosis and Treatment of Pulmonary Embolism

100 Years of Sanatorium in Rudka—Report of Celebration of Anniversary